: Elon Musk’s Neuralink says it has FDA approval for first human clinical study


Elon Musk’s Neuralink said Thursday it has received regulatory approval to start the first in-human clinical study for its brain implant.

“We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study!” the company tweeted Thursday. “This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people.”

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleIcahn’s IEP stock has now lost 63% since a critical short-seller report on May 2
Next article: Domo stock drops nearly 7% after mixed Q1 results


Please enter your comment!
Please enter your name here